Login to Your Account



J.P. Morgan Healthcare Conference

FDA Offers Orexigen Express Route to Contrave Resubmission

By Lynn Yoffee
Executive Editor

Wednesday, January 9, 2013
If just 6 percent of diabetes patients who are obese take Orexigen Therapeutics Inc.'s Contrave (naltrexone SR/bupropion SR), the company will reach $1 billion in sales in short order – assuming the FDA grants approval. Given the agency's action this week, company execs have reason to feel confident.

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription